PROTOKINETIX, INCORPORATED

PKTX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item Sep 2026 Dec 2025 Nov 2025 Sep 2025 Aug 2025 Jun 2025 May 2025 Mar 2025
Revenue
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $24.2K $24.4K $33.8K
SG&A Expense $16.2K $14.1K $14.7K
Operating Income
Operating Margin
Interest Expense
Pretax Income
Income Tax Expense
Net Income $-84.9K $-91.1K $-97.7K
Net Margin
EPS (Basic) $0.00 $0.00 $0.00
EPS (Diluted) $0.00 $0.00 $0.00
Shares Outstanding (Basic) 411.6M 406.8M 391.6M 389.4M 389.1M 354.0M 388.6M 374.1M
Shares Outstanding (Diluted) 411.6M 406.8M 391.6M 389.4M 389.1M 354.0M 388.6M 374.1M
Dividends Per Share
← Newer Page 1 of 15 Older →